SNC-162

SNC-162

SNC-162 is a chemical compound that has been studied for its potential effects on the central nervous system. It is classified as a synthetic opioid and is structurally related to other compounds in the benzomorphan class. SNC-162 has been of interest in pharmacological research due to its unique properties and potential therapeutic applications.

Chemical Structure and Properties

SNC-162 belongs to the benzomorphan class of opioids, which are characterized by their distinct chemical structure. The compound has a complex molecular framework that includes a benzene ring fused to a morphinan skeleton. This structure is responsible for its interaction with opioid receptors in the brain.

The chemical formula of SNC-162 is C20H25NO, and it has a molecular weight of 295.42 g/mol. The compound is typically synthesized in a laboratory setting and is not found naturally.

Pharmacology

SNC-162 acts primarily as an agonist at the kappa-opioid receptor (KOR). This receptor is one of the three main types of opioid receptors, the others being the mu-opioid receptor (MOR) and the delta-opioid receptor (DOR). Activation of the KOR by SNC-162 can lead to a variety of effects, including analgesia, dysphoria, and hallucinations.

Mechanism of Action

The mechanism of action of SNC-162 involves binding to the kappa-opioid receptors in the central nervous system. Upon binding, SNC-162 induces a conformational change in the receptor, leading to the activation of intracellular signaling pathways. This results in the modulation of neurotransmitter release and changes in neuronal excitability.

Therapeutic Potential

Research into SNC-162 has explored its potential use in treating conditions such as pain, depression, and addiction. The kappa-opioid receptor system is known to play a role in mood regulation and stress response, making SNC-162 a candidate for further investigation in these areas.

Research and Development

Studies on SNC-162 have primarily been conducted in preclinical settings, using animal models to assess its pharmacological effects. These studies have provided insights into the compound's efficacy and safety profile, although more research is needed to fully understand its potential clinical applications.

Safety and Side Effects

As with other kappa-opioid receptor agonists, SNC-162 may produce side effects such as dysphoria, sedation, and hallucinations. The safety profile of SNC-162 in humans has not been fully established, and caution is advised when interpreting preclinical data.

Legal Status

The legal status of SNC-162 varies by country. In many jurisdictions, it is considered a research chemical and is not approved for medical use. Researchers must comply with local regulations when studying SNC-162.

Also see

• Opioid receptor
• Kappa-opioid receptor
• Benzomorphan
• Analgesic
• Synthetic opioid